Premium
MAb C11C1, a monoclonal antibody to cleaved high molecular weight kininogen (HK) inhibits murine tumor metastasis in syngeneic hosts
Author(s) -
Khan Sabina T,
Pixley Robin A,
Liu Yuchuan,
Gordon Bridgette,
Huang Yajue,
Agelan Alexis,
Achary Mohan,
Colman Robert W
Publication year - 2009
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.23.1_supplement.927.10
Subject(s) - medicine , melanoma , metastasis , monoclonal antibody , antibody , pathology , cancer , lung , cancer research , immunology
Metastasis of malignant tumors is a major cause of morbidity and mortality. We previously demonstrated that C11C1 has the ability to reduce tumor growth in murine multiple myeloma in mice and human colon cancer in nude mice. Normal mice treated with C11C1 did not show any gross or histological evidence of organ damage or hemorrhage. We now evaluate the antimetastatic effect of C11C1 on C57BL/6 mouse lung metastatic model using B16F10 melanoma cells. In two separate studies, tail veins of mice were injected with melanoma cells. Each study included two groups of mice. One group received C11C1 and the other received saline (control) intraperitoneally. In one study all the mice were euthanized at 28 days and in the second 52 days, to allow a longer time period to develop metastases. In the 28 day control group, 6 of 10 mice had detectable metastatic pulmonary nodules. In the 52 day control group 5 of 9 mice had metastases. There was no relation of the incidence of metastases to the duration of the study. The metastatic nodules stained positive with an antibody against S‐100 protein, a tumor antigen which is present in B16 F10 cells. In the C11C1 groups, (Fisher Exact test) 0 of 10 mice (p=0.017) and 0 of 13 mice (p=0.005) showed no metastatic foci in their lungs. These studies demonstrate that a monoclonal antibody to HK has a therapeutic potential with minimal side effects in the treatment of metastatic cancer. NIH 2T32HL007777 & 5RO1CA83121.